A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM 31510 in Healthy Subjects
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Basal cell cancer; Leukaemia; Lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Wounds
- Focus Pharmacokinetics
- Sponsors Berg Pharma
Most Recent Events
- 07 Jan 2016 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jul 2015 New trial record